Copy
View this email in your browser
This week’s podcast:
Marilyn Huestis, PhD, on Marijuana Tolerance
 
Key Points 
  • Occasional user needs lower amount of THC to get high
  • Chronic frequent user needs quite a bit more to get same high
  • Some evidence showing cannabis can change the proteins that surround your DNA and determine what genes are going to reproduce.
  • Those changes are heritable, meaning if you use, it may affect your unborn children. 
Listen to Dr. Huestis on Marijuana Tolerance here.

Up next week? Mahmoud ElSohly, PhD – Is marijuana the same as Epidiolex?

 
Seattle metro area is one of just three in America where marijuana use tops nicotine, data shows
 
Past-month marijuana use among those age 18 and older now tops tobacco use, including e-cigarettes, in Seattle, San Francisco, and Portland:
 
Seattle
Past-month marijuana use -- 17 percent
Past-month tobacco use – 16 percent
 
San Francisco
Past-month marijuana use -- 16 percent
Past-month tobacco use – 13 percent
 
Portland
Past-month marijuana use -- 20 percent
Past-month tobacco use – 19 percent
 
In Seattle, 17 percent translates into about 700,000 people 18 and older who are using marijuana regularly. We note that the legal age to buy recreational marijuana in all three states is 21, not 18.
 
Nielsen surveyed more than 200,000 adults nationally to produce these findings.
 
Legal pot sales began in Michigan over Thanksgiving weekend, but the state’s cities are not likely to experience marijuana use like those in the West. Some 80 percent of Michigan cities have banned marijuana sales within their borders.
 
Read Seattle Times story hereRead Vox article here.
 
Is that a vaping device? Take this quiz
 
To help parents, teachers, and school administrators keep vaping products away from kids, the Atlanta Journal Constitution offers a quiz showing a variety of such devices mixed with devices that have nothing to do with vaping.
 
Test your vaping IQ here.

 
Federal addiction treatment dollars off limits for marijuana
 
Federal funds designated for treating opioid addiction, other addictions, or mental health disorders cannot be used to pay for “medical” marijuana as a treatment.
 
“There’s zero evidence for that,” says Dr. Elinore McCance-Katz, administrator of the Substance Abuse and Mental Health Services Administration. “We felt is was time to make it clear we did not want individuals receiving funds for treatment services to be exposed to marijuana and somehow given the impression that it’s a treatment,” she continues.
 
The restriction applies to two main grant programs for opioid treatment and the older block grant for treating alcoholism and drug addiction, amounting to billions of dollars.
 
On a similar note, the American Society for Addiction Medicine (ASAM) has derived a new definition of addiction:
 
Addiction is a treatable, chronic medical disease involving complex interactions among brain circuits, genetics, the environment, and an individual’s life experiences. People with addiction use substances or engage in behaviors that become compulsive and often continue despite harmful consequences. 
Prevention efforts and treatment approaches for addiction are generally as successful as those for other chronic diseases. 
 
Read Village News story about SAMHSA here
Read more about ASAM’s new definition of addiction here.

 
Field test kits will help police
distinguish between marijuana and hemp
 
The Virginia Department of Forensic Science (DFS) is distributing more than 16,000 kits to law enforcement agencies to distinguish illegal marijuana from legal hemp. The two plants look and smell the same, but hemp contains less than 0.3% (three tenths of one percent) THC, while marijuana contains higher levels of the psychoactive component.
 
A traditional test to identify marijuana will be used first, then the new test kit, 4-AP, will be used to determine whether the plant material contains higher levels of THC (the material turns blue) or higher levels of CBD (the material turns pink).
 
A brief video explaining how the test works is available from the DFS website here.
Read Daily Progress story here.

 
What you need to know (and what we’re working to find out) about products containing cannabis or cannabis-derived compounds, including CBD
 
The FDA issued a statement to educate the public about CBD. Key points include: 
  • FDA has approved only one CBD product, Epidiolex, to treat two rare forms of epilepsy.
  • Adding CBD to food or labeling it as a dietary supplement is illegal.
  • Limited data about CBD’s safety point to real risks.
  • Some CBD products are being marketed with unproven medical claims and are of unknown quality. 
1. CBD can harm you even before you become aware of it.
  • CBD can cause liver injury.
  • CBD can interfere other drugs, causing serious side effects.
  • CBD used with alcohol or other depressants increases the risk of sedation and drowsiness, which can lead to injuries. 
2. CBD can cause side effects that should improve when use stops or is reduced.
  • Drowsiness or sleepiness.
  • Diarrhea and/or decreased appetite.
  • Mood changes such as irritability and agitation. 
3. There is much about CBD not yet known, such as:
  • What happens if you take CBD daily long-term?
  • What effect does CBD have on the developing brain?
  • How does CBD affect the developing fetus or breastfed newborn?
  • How does CBD interact with herbs and botanicals?
  • Does CBD cause male reproductive toxicity in humans, as it does in studies of animals? 
Read FDA Statement on CBD here.

View several warning letters FDA has sent CBD manufacturers here.

 
2,290 vaping-related lung injury cases,
47 deaths as of November 20, 2019
 
The cases have been reported in all states but Alaska, and in Puerto Rico and the US Virgin Islands. CDC has identified vitamin E acetate as a chemical of concern. However, evidence is not yet sufficient to rule out other chemicals.
 
CDC issued no report during the week of Thanksgiving. Its next report is due tomorrow, December 5.
 
Read current CDC report here.

 
31,000-plus scientific studies on marijuana
are available from Pub Med
 
A colleague, Jay le Blanc, was curious about how many studies scientists have conducted on marijuana/cannabis. He was also interested in finding studies related to the following conditions: violence, murder, birth defects, psychosis, schizophrenia, bipolar disease, and the endocrine system.
 
He visited online Pub Med, a service of the National Institute of Health’s US National Library of Medicine. Here’s what he found using the following search terms:
 
Cannabis
Marijuana
31,570 publications
Date range: 2019 to 1840
 
Cannabis violence
Marijuana violence
887 publications
Date range: 2019 to 1968
 
Cannabis murder
Marijuana murder
70 publications
Date range: 2019 to 1976
 
Cannabis birth defects
Marijuana birth defects
466 publications
Date range: 2019 to 1964
 
Cannabis psychosis
Marijuana psychosis
2,117 publications
Date range: 2019 to 1948
 
Cannabis schizophrenia
Marijuana schizophrenia
1,547 publications
Date range: 2019 to 1962
 
Cannabis bipolar
Marijuana bipolar
345 publications
Date range: 2019 to 1969 
Visit The Marijuana Report’s Facebook page
In addition to current issues of The Marijuana Report, we post several more marijuana messages each month on our Facebook page. Search Facebook for nationalfamilies to access it.
 

Looking for a past issue of The Marijuana Report?
  Find it here.

Did you know
that in addition to The Marijuana Report e-newsletter, National Families in Action also publishes The Marijuana Report website? There you can find summaries of (and access to) scientific marijuana studies, the growth of the commercial marijuana industry, and what families and communities are doing to restrain it. Begin at our Welcome Page to access all the resources The Marijuana Report website offers.
 
The Marijuana Report is a weekly e-newsletter published by National Families in Action in partnership with SAM (Smart Approaches to Marijuana).

Visit National Families in Action's website, The Marijuana Report.Org, to learn more about the marijuana story unfolding across the nation.

Subscribe to The Marijuana Report e-newsletter.
Giving Tuesday is gone,
but you can still donate to The Marijuana Report.
Thank you!


The Marijuana Report Staff
Executive Editor
Sue Rusche
Editor
Nicole Carter
Proofreading
Harry Rusche, Professor Emeritus
IT Consultant
Lee Clontz
Social Media Coordinator
Margarita Eberline
 
We are grateful to our Board of Directors and Senior Adviser for their support of National Families in Action, which produces The Marijuana Report website and e-newsletter.
 
National Families in Action
Board of Directors

William F. Carter, Chairman of the Board
Realtor Berkshire Hathaway HomeServices – Georgia Properties, Atlanta.
Sue Rusche, President and CEO, Atlanta.
Richard L. Brown, Secretary
Attorney (Ret.), Lakewood Ranch, Florida
Founder & Chairman, Sudden Cardiac Arrest Association 
Jeannine F. Adams, Director
President and CEO, J. Addams & Partners, Atlanta.
Jack L. Arbiser, MD, PhD, Director
Thomas J. Lawley Professor of Dermatology
Winship Cancer Institute, Emory University, Atlanta
William H. Avery, Director
Partner (Ret.), Alston & Bird, LLP, Atlanta.
Margarita Eberline, Director
Strategy Director, 360 Marketing Plus, Atlanta.
Robert Margolis, PhD, Director
Founder, Caron Solutions Intensive Outpatient Program, Roswell, Georgia.
Shannon Murphy, MD FAAP, Director
Birmingham, Alabama 
 
Senior Adviser
Kent “Oz” Nelson, Chairman and CEO (Ret.)
United Parcel Service, Atlanta.
 
National Families National Families
National Families National Families
National Families National Families
The MJ Report The MJ Report
The MJ Report The MJ Report
The MJ Report The MJ Report

Note: If someone forwarded this to you, please do not unsubscribe. Clicking the Unsubscribe button will end that person's subscription. Instead, please ask the person who forwarded this to you to take you off his or her forwarding list. Thank you!
Copyright © 2019 National Families in Action, All rights reserved.


unsubscribe from this list    update subscription preferences